The DOI matches its Crossref record; its reference list is not available.
Identification of an SFRP1 inhibitor as a novel therapeutic strategy for cancers using dry-wet combined drug discovery strategy
Open accessPreprint — published as 10.1007/s11030-026-11586-3
Abstract
Secreted frizzled-related protein 1 (SFRP1) exerts a context-dependent dual role in cancer, and its epigenetic silencing drives pro-tumorigenic non-canonical Wnt activation, a promising therapeutic target for advanced malignancies. In this study, a validated 3D SFRP1 model was built by comprehensive computational approach. High-throughput virtual screening of a commercial compound library identified a common core scaffold, which was rationally design to synthesize lead compound. The target molecule was synthesized via organic synthetic approaches. Surface plasmon resonance (SPR) assays confirmed the specific binding of compound L1 to SFRP1 with a dissociation constant (KD) of 79.1 nM. Furthermore, molecular docking and molecular dynamics (MD) simulation elucidated the interaction between compound L1 and SFRP1 at the molecular level and in physiological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 29
Research works printed but not linked: 27
- Bhat RA, Stauffer B, Komm BS, Bodine PV (2007) Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. J Cell Biochem 102:1519–1528 · DOI
- Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJ, Arfuso F, Fox SA, Dharmarajan AM, Kumar AP (2014) Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 1845:53–65
- Zhang W, Zhang K, Ma Y, Song Y, Qi T, Xiong G, Zhang Y, Kan C, Zhang J, Han F, Sun X (2023) Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition. Biomed Pharmacother 166:115344 · DOI · Paper page
- Saini S, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H, Dahiya R (2009) Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res 69:6815–6822 · DOI
- Bernemann C, Hulsewig C, Ruckert C, Schafer S, Blumel L, Hempel G, Gotte M, Greve B, Barth PJ, Kiesel L, Liedtke C (2014) Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Mol Cancer 13:174 · DOI
- Qu Y, Ray PS, Li J, Cai Q, Bagaria SP, Moran C, Sim MS, Zhang J, Turner RR, Zhu Z, Cui X, Liu B (2013) High levels of secreted frizzled-related protein 1 correlate with poor prognosis and promote tumourigenesis in gastric cancer. Eur J Cancer 49:3718–3728 · DOI
- Jothimani M, Vijayaraghavalu S, Sadasivam K, Muthusamy K (2025) Identification of Potent SFRP1 Inhibitors for Colorectal Cancer using a Comprehensive Computational Approach. Curr Comput Aided Drug Des 21:1022–1035 · DOI
- Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888 · DOI · Paper page
- Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, Tao Q, Xu H (2022) Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer 21:144 · DOI · Paper page
- Subramaniam S, Mehrotra M, Gupta D (2008) Virtual high throughput screening (vHTS)--a perspective. Bioinformation 3:14–17 · DOI
- Banegas-Luna AJ, Ceron-Carrasco JP, Perez-Sanchez H (2018) A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data. Future Med Chem 10:2641–2658 · DOI
- Wang S, Jiang JH, Li RY, Deng P (2020) Docking-based virtual screening of TbetaR1 inhibitors: evaluation of pose prediction and scoring functions. BMC Chem 14:52 · DOI
- Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8:477–486 · DOI · Paper page
- Colovos C, Yeates TO (1993) Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2:1511–1519 · DOI · Paper page
- Wiederstein M, Sippl MJ (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 35:W407–410 · DOI · Paper page
- Krivak R, Hoksza D (2018) P2Rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure. J Cheminform 10:39 · DOI · Paper page
- Polak L, Skoda P, Riedlova K, Krivak R, Novotny M, Hoksza D (2025) PrankWeb 4: a modular web server for protein-ligand binding site prediction and downstream analysis. Nucleic Acids Res 53:W466–W471 · DOI
- Rao SN, Head MS, Kulkarni A, LaLonde JM (2007) Validation studies of the site-directed docking program LibDock. J Chem Inf Model 47:2159–2171 · DOI · Paper page
- Alrouji M, Yasmin S, Alshammari MS, Alhumaydhi FA, Sharaf SE, Shahwan M, Shamsi A (2025) Virtual screening and molecular dynamics simulations identify repurposed drugs as potent inhibitors of Histone deacetylase 1: Implication in cancer therapeutics. PLoS ONE 20:e0316343 · DOI
- Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 · DOI · Paper page
- Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174 · DOI · Paper page
- Tatamidani H, Kakiuchi F, Chatani N (2004) A new ketone synthesis by palladium-catalyzed cross-coupling reactions of esters with organoboron compounds. Org Lett 6:3597–3599 · DOI
- Pattnaik P (2005) Surface plasmon resonance: applications in understanding receptor-ligand interaction. Appl Biochem Biotechnol 126:79–92 · DOI · Paper page
- Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36:1461–1473 · DOI · Paper page
- Vincent KM, Postovit LM (2017) A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function. Sci Rep 7:42719 · DOI
- Kahn M (2014) Can we safely target the WNT pathway? Nat Rev Drug Discov 13:513–532 · DOI · Paper page
- Losada-Garcia A, Salido-Guadarrama I, Cortes-Ramirez SA, Cruz-Burgos M, Morales-Pacheco M, Vazquez-Santillan K, Rodriguez-Martinez G, Gonzalez-Ramirez I, Gonzalez-Covarrubias V, Perez-Plascencia C, Rodriguez-Dorantes M (2023) SFRP1 induces a stem cell phenotype in prostate cancer cells. Front Cell Dev Biol 11:1096923 · DOI
Metadata
- Authors
- Yunlong, Z., Ruiqi, W., Meihong, P., Nan, Q., Xiaopeng, W., & Jun, S.
- Affiliations
- Tianjin Medical University Cancer Institute and Hospital
- Tianjin Medical University (CN)
- Tianjin Medical University
- Corresponding author
- Ruiqi, Wei
- Venue
- Molecular Diversity
- Published
- 2026-04-25
- Volume
- 30
- Issue
- 5
- Pages
- 7429-7439
- ISSN
- 1381-1991 (ISSN-L)
- OpenAlex
- W7162509783
- Cited by
- 0
- References
- 29
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Molecular Diversity (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- SFRP1, non-canonical Wnt signaling, epigenetic silencing, cancer therapy, 3D protein model, virtual screening, lead compound synthesis, protein-ligand binding, molecular docking, molecular dynamics simulation, surface plasmon resonance
- MeSH terms
- Secreted Frizzled-Related Proteins, Antineoplastic Agents, Humans, Membrane Proteins, Neoplasms, Protein Binding, Intercellular Signaling Peptides and Proteins, Drug Discovery, Molecular Dynamics Simulation, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of an SFRP1 inhibitor as a novel therapeutic strategy for cancers using dry-wet combined drug discovery strategy. https://app.cochat.ai/papers/10.21203/rs.3.rs-9393160/v1
- The paper
- Yunlong, Z., Ruiqi, W., Meihong, P., Nan, Q., Xiaopeng, W., & Jun, S. (2026). Identification of an SFRP1 inhibitor as a novel therapeutic strategy for cancers using dry-wet combined drug discovery strategy. Molecular Diversity. https://doi.org/10.21203/rs.3.rs-9393160/v1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.